. . "Cephaloglycin"@en . . . "For treatment of severe infections caused by susceptible bacteria."@en . . . . "Cefaloglycine"@en . . "approved"@en . "The bactericidal activity of cephaloglycin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs)."@en . . "D-Cephaloglycine"@en . . . . "Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions."@en . . . "3577-01-3"@en . . . . "7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid"@en . . "7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid"@en . "Enteric bacteria and other eubacteria"@en . . . . . "Cephaoglycin acid"@en . "CEG"@en . " "@en . . "# Tune BM, Hsu CY: The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol. 1990 Nov;1(5):815-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2133431 # Tune BM, Fravert D, Hsu CY: Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin. Biochem Pharmacol. 1989 Mar 1;38(5):795-802. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2930580"@en . . . . "A cephalorsporin antibiotic that is no longer commonly used. "@en . "Cefaloglycinum"@en . "D-(-)-Cephaloglycin"@en . . . . . . . . . "Wall, W.F., Fatherey, M. and Boothroyd, 6.; U.S. Patent 3,422,103; January 14,1969; assigned to Glaxo Laboratories, Ltd. Pfeiffer, R.R. and Bottorff, E.M.; US. Patent 3,497,505; February 24,1970; assigned to Eli Lilly & Co. Jackson, B.G.; U.S. Patent 3,671,449; June 20,1972; assigned to Eli Lilly & Co."@en . . . . "7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid"@en . "Cephaloglycine"@en . . . . "Well absorbed following oral administration."@en . . "Cefaloglicina"@en .